I’ve spent a good part of my career arguing that anti-obesity drugs like Meridia and fenphen have serious side effects, are not terribly effective, and should be taken off the market. Several have been.
FDA alerts online shoppers that tejocote root supplements may be toxic yellow oleander; Amazon warned to stop selling mislabeled erectile dysfunction drugs.
In May, the Food and Drug Administration approved tirzepatide—which patients inject under their skin weekly—to treat type 2 diabetes, because in clinical trials it cut hemoglobin A1c levels (a long-term measure of blood sugar) even more than taking insulin. The FDA has not yet approved tirzepatide for weight loss. But that may soon happen.
Roughly 40 percent of U.S. adults have obesity. Another 30 percent have overweight. Extra pounds raise the risk of type 2 diabetes, heart disease, stroke, several cancers, and more. Here’s the latest on what’s driving weight gain and two new medications that may revolutionize its treatment.
The Center for Science in the Public Interest applauds the California state legislature for passing AB-1341, a bill that would ban the sale of over-the-counter diet pills and weight-loss supplements to minors in California.